BAXTER INTERNATIONAL INC acquires Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson)
Snapshot
BAXTER INTERNATIONAL INC acquired Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson) for approximately $325 million in cash in February 2021. The transaction was structured as all cash. Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson) is a Rights for territories outside the United States (acquired from a Johnson & Johnson subsidiary)-based Oncology pharmaceuticals business.
- Acquirer
- BAXTER INTERNATIONAL INC
- Target
- Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson)
- Value
- approximately $325 million in cash
- Date
- February 2021
- Type
- asset purchase
- Status
- ready
The deal at a glance
About this deal
BAXTER INTERNATIONAL INC acquired Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson) for approximately $325 million in cash, a transaction completed in February 2021, structured as all cash. The deal was a asset purchase.
Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson) operates in Oncology pharmaceuticals, is based in Rights for territories outside the United States (acquired from a Johnson & Johnson subsidiary). Caelyx and Doxil are the branded versions of liposomal doxorubicin, a chemotherapy medicine used to treat various types of cancer; Baxter acquired the rights for specified territories outside the U.S. from a subsidiary of Johnson & Johnson (having previously acquired the U.S. rights to the product in 2019).
Expands Baxter's pharmaceuticals portfolio with an established branded oncology product, completing its global rights to liposomal doxorubicin.
Completed Baxter's global rights to an established branded oncology product (liposomal doxorubicin). Integrated into Baxter's pharmaceuticals business
No advisory firms have been disclosed for this transaction.